3p22.1 and 10q22.3 deletions detected by Fluorescence in Situ Hybridization (FISH): A potential new tool for early detection of non-small cell lung cancer (NSCLC)

Journal of Thoracic Oncology

Volumn 3, Issue 9, 2008, Pages 979-984

  Yendamuri, Sai ^a   Vaporciyan, Ara A ^b   Zaidi, Tanweer ^b   Feng, Lei ^b   Fernandez, Ricardo ^b   Bekele, Nebiyou B ^b   Hofstetter, Wayne L ^b   Jiang, Feng ^c   Mehran, Reza J ^b   Rice, David C ^b   Spitz, Margaret R ^b   Swisher, Stephen G ^b   Walsh, Garrett L ^b   Roth, Jack A ^b   Katz, Ruth L ^b  

^a ROSWELL PARK CANCER INSTITUTE   (United States)

^b UNIVERSITY OF TEXAS   (United States)

^c UNIVERSITY OF MARYLAND SCHOOL OF MEDICINE   (United States)

Author keywords

Bronchial brushes; Cancer; Fluorescent in situ hybridization; Lung; Non small cell; Screening

Indexed keywords

ADULT; AGED; ARTICLE; BRONCHUS; CANCER DIAGNOSIS; CANCER SURGERY; CHROMOSOME 10Q; CHROMOSOME 3P; CHROMOSOME DELETION; CONTROLLED STUDY; FEASIBILITY STUDY; FEMALE; FLUORESCENCE IN SITU HYBRIDIZATION; HUMAN; HUMAN CELL; HUMAN TISSUE; LUNG NON SMALL CELL CANCER; LUNG PARENCHYMA; MAJOR CLINICAL STUDY; MALE; MOLECULAR PROBE; PRIORITY JOURNAL; ADENOCARCINOMA; CANCER STAGING; CELL DIFFERENTIATION; CHROMOSOME 10; CHROMOSOME 3; COHORT ANALYSIS; EARLY DIAGNOSIS; GENETICS; LUNG TUMOR; METHODOLOGY; MIDDLE AGED; PATHOLOGY; PROGNOSIS; SQUAMOUS CELL CARCINOMA; SURVIVAL RATE;

ADENOCARCINOMA; ADULT; AGED; AGED, 80 AND OVER; BRONCHI; CARCINOMA, NON-SMALL-CELL LUNG; CARCINOMA, SQUAMOUS CELL; CELL DIFFERENTIATION; CHROMOSOME DELETION; CHROMOSOMES, HUMAN, PAIR 10; CHROMOSOMES, HUMAN, PAIR 3; COHORT STUDIES; EARLY DIAGNOSIS; FEMALE; HUMANS; IN SITU HYBRIDIZATION, FLUORESCENCE; LUNG NEOPLASMS; MALE; MIDDLE AGED; NEOPLASM STAGING; PROGNOSIS; SURVIVAL RATE;

EID: 58149134374     PISSN: 15560864     EISSN: 15561380     Source Type: Journal    
DOI: 10.1097/JTO.0b013e3181834f3a     Document Type: Article

References (23)

1. Lee PC, Korst RJ, Port JL, et al. Long-term survival and recurrence in patients with resected non-small cell lung cancer 1 cm or less in size. J Thorac Cardiovasc Surg 2006;132:1382-1399.
2. Petty TL. Sputum cytology for the detection of early lung cancer. Curr Opin Pulm Med 2003;9:309-312.
3. Lam S, Kennedy T, Unger M, et al. Localization of bronchial intraepithelial neoplastic lesions by fluorescence bronchoscopy. Chest 1998; 113:696-702.
4. Romeo MS, Sokolova IA, Morrison LE, et al. Chromosomal abnormalities in non-small cell lung carcinomas and in bronchial epithelia of high-risk smokers detected by multi-target interphase fluorescence in situ hybridization. J Mol Diagn 2003;5:103-112.
5. Varella-Garcia M, Kittelson J, Schulte AP, et al. Multi-target interphase fluorescence in situ hybridization assay increases sensitivity of sputum cytology as a predictor of lung cancer. Cancer Detect Prev 2004;28: 244-251.
6. Jiang F, Katz RL. Use of interphase fluorescence in situ hybridization as a powerful diagnostic tool in cytology. Diagn Mol Pathol 2002;11: 47-57.
7. Savic S, Glatz K, Schoenegg R, et al. Multitarget fluorescence in situ hybridization elucidates equivocal lung cytology. Chest 2006;129: 1629-1635.
8. Jiang F, Yin Z, Caraway NP, Li R, Katz RL. Genomic profiles in stage I primary non small cell lung cancer using comparative genomic hybridization analysis of cDNA microarrays. Neoplasia 2004;6:623-635.
9. Barkan GA, Caraway NP, Jiang F, et al. Comparison of molecular abnormalities in bronchial brushings and tumor touch preparations. Cancer 2005;105:35-43.
10. Henschke CI; for the International Early Lung Cancer Action Program Investigators. Survival of patients with stage I lung cancer detected on CT screening. N Engl J Med 2006;355:1763-1771.
11. Henschke CI. CT screening for lung cancer is justified. Nat Clin Pract Oncol 2007;4:440-441.
12. Taylor WF, Fontana RS, Uhlenhopp MA, Davis CS. Some results of screening for early lung cancer. Cancer 1981;47(5 Suppl):1114-1120.
13. Halling KC, Rickman OB, Kipp BR, et al. A comparison of cytology and fluorescence in situ hybridization for the detection of lung cancer in bronchoscopic specimens. Chest 2006;130:694-701.
14. Kohno T, Yokota J. How many tumor suppressor genes are involved in human lung carcinogenesis? Carcinogenesis 1999;20:1403-1410.
15. Niklinski J, Hirsch FR. Molecular approaches to lung cancer evaluation. Lung Cancer 2002;38 (Suppl 3):S9-S17.
16. Zabarovsky ER, Lerman MI, Minna JD. Tumor suppressor genes on chromosome 3p involved in the pathogenesis of lung and other cancers. Oncogene 2002;21:6915-6935.
17. Pekarsky Y, Palamarchuk A, Huebner K, Croce CM. FHIT as tumor suppressor: mechanisms and therapeutic opportunities. Cancer Biol Ther 2002;1:232-236.
18. Ito I, Tanaka F, Saito Y, et al. Liposomal vector mediated delivery of the 3p FUS1 gene demonstrates potent antitumor activity against human lung cancer in vivo. Cancer Gene Ther 2004;11:733-739.
19. Bruns G, Stroh H, Veldman GM, Latt SA, Floros J. The 35 kd pulmonary surfactant-associated protein is encoded on chromosome 10. Hum Genet 1987;76:58-62.
20. O'Reilly MA Gazdar AF, Morris RE, Whitsett JA. Differential effects of glucocorticoid on expression of surfactant proteins in a human lung adenocarcinoma cell line. Biochim Biophys Acta 1988;970:194-204.
21. Tsutsumida H, Goto M, Kitajima S, et al. Combined status of MUC1 mucin and surfactant apoprotein A expression can predict the outcome of patients with small-size lung adenocarcinoma. Histopathology 2004; 44:147-155.
22. Jiang F, Caraway NP, Bekele BN, et al. Surfactant protein A gene deletion and prognostics for patients with stage I non-small cell lung cancer. Clin Cancer Res 2005;11:5417-5424.
23. Katz RL, Zaidi TM, Fernandez RL, et al. Automated detection of genetic abnormalities combined with cytology in sputum is a sensitive predictor of lung cancer. Mod Path 2008;21:950-960.